What category does this event fall under?

Business — classified as earnings report.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Natco Pharma reported profit decline · Natco Pharma approved QIP raise · Natco Pharma approved interim dividend

Is this event still developing?

This is an active story, last updated Aug 14, 2026. Coverage continues to evolve.

Business earnings report

Natco Pharma Q1 profit slumps 57%

Q: When did this event occur?

First reported Aug 14, 2026; last updated Aug 14, 2026.

Q: What is the market impact?

General. The sharp profit decline and weak revenue from lenalidomide are likely to pressure Natco Pharma's stock price in the near term.

Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Aug 14, 2026

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The sharp profit decline and weak revenue from lenalidomide are likely to pressure Natco Pharma's stock price in the near term. The approved QIP may provide some support by strengthening the company's balance sheet for future growth.

Pharmaceuticals

Event Summary

Natco Pharma reported a 57% year-on-year decline in consolidated net profit for Q1 FY27, falling to Rs 206.5 crore from Rs 480.3 crore in the same quarter last year. Revenue from operations dropped 44.7% to Rs 735.2 crore, primarily due to lower sales of its generic cancer drug lenalidomide, which significantly impacted its international business. EBITDA declined 67.4% to Rs 186 crore, with margins contracting to 25.3% from 43%. Domestic formulations and API segments showed growth, but international formulations revenue fell sharply. The board approved an interim dividend of Rs 1.50 per share and a proposal to raise up to Rs 2,000 crore through a QIP.

Key Actions

100 Natco Pharma reported profit decline

50 Natco Pharma approved QIP raise

30 Natco Pharma approved interim dividend

Entities Involved

stock

Natco Pharma

Natco Pharma is the reporting company; its Q1 results show a significant profit decline due to lower lenalidomide sales, impacting its financial performance and market perception.

Importance 100.0 Sentiment -40.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard